ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment
- PMID: 38579085
- PMCID: PMC10994465
- DOI: 10.1097/MD.0000000000037590
ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment
Abstract
Background: 5-Methylcytidine (m5C) methylation is a recently emerging epigenetic modification that is closely related to tumor proliferation, occurrence, and metastasis. This study aimed to investigate the clinicopathological characteristics and prognostic value of m5C regulators in bladder cancer (BLCA), and their correlation with the tumor immune microenvironment.
Methods: Thirteen m5C RNA methylation regulators were analyzed using RNA-sequencing and corresponding clinical information obtained from the TCGA database. The Cluster Profiler package was used to analyze the gene ontology function of potential targets and enriched the Kyoto Encyclopedia of Genes and Genomes pathway. Kaplan-Meier survival analysis was used to compare survival differences using the log-rank test and univariate Cox proportional hazards regression. The correlation between signature prognostic m5C regulators and various immune cells was analyzed. Univariate and multivariate Cox regression analyses identified independence of the ALYREF gene signature.
Results: Nine out of the 13 m5C RNA methylation regulators were differentially expressed in BLCA and normal samples and were co-expressed. These 9 regulators were associated with clinicopathological tumor characteristics, particularly high or low tumor risk, pT or pTNM stage, and migration. Consensus clustering analysis divides the BLCA samples into 4 clusters. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment annotation and gene ontology function analysis identified 273 upregulated and 594 downregulated genes in BLCA. Notably, only ALYREF was significantly correlated with OS (P < .05). ALYREF exhibited significant infiltration levels in macrophage cells. Therefore, we constructed a nomogram for ALYREF as an independent prognostic factor. Additionally, we observed that both the mRNA and protein levels of ALYREF were upregulated, and immunofluorescence showed that ALYREF was mainly distributed in nuclear speckles. ALYREF overexpression was significantly associated with poor OS.
Conclusion: Our findings demonstrated the potential of ALYREF to predict clinical prognostic risks in BLCA patients and regulate the tumor immune microenvironment. As such, ALYREF may serve as a novel prognostic indicator in BLCA patients.
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no funding and conflicts of interest to disclose.
Figures









Similar articles
-
Exploration and validation of a novel reactive oxygen species-related signature for predicting the prognosis and chemotherapy response of patients with bladder cancer.Front Immunol. 2024 Dec 19;15:1493528. doi: 10.3389/fimmu.2024.1493528. eCollection 2024. Front Immunol. 2024. PMID: 39749345 Free PMC article.
-
Comprehensive analysis of RNA methylation-related genes to identify molecular cluster for predicting prognosis and immune profiles in bladder cancer.Sci Rep. 2025 Mar 17;15(1):9147. doi: 10.1038/s41598-025-93674-2. Sci Rep. 2025. PMID: 40097551 Free PMC article.
-
TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.J Exp Clin Cancer Res. 2022 May 17;41(1):175. doi: 10.1186/s13046-022-02377-3. J Exp Clin Cancer Res. 2022. PMID: 35581606 Free PMC article.
-
Phosphorus Metabolism-Related Genes Serve as Novel Biomarkers for Predicting Prognosis in Bladder Cancer: A Bioinformatics Analysis.Iran J Public Health. 2024 Sep;53(9):1935-1950. doi: 10.18502/ijph.v53i9.16449. Iran J Public Health. 2024. PMID: 39429662 Free PMC article. Review.
-
Biological functions of 5-methylcytosine RNA-binding proteins and their potential mechanisms in human cancers.Front Oncol. 2025 Feb 7;15:1534948. doi: 10.3389/fonc.2025.1534948. eCollection 2025. Front Oncol. 2025. PMID: 39990690 Free PMC article. Review.
Cited by
-
The role of m5C RNA modification in cancer development and therapy.Heliyon. 2024 Sep 27;10(19):e38660. doi: 10.1016/j.heliyon.2024.e38660. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39444404 Free PMC article. Review.
-
The role of m5C, m1A and m7G modifications in tumors of urinary system.Front Cell Dev Biol. 2025 Jul 30;13:1549588. doi: 10.3389/fcell.2025.1549588. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40809690 Free PMC article. Review.
-
The role and clinical potential of RNA modifications in bladder cancer.Bladder (San Franc). 2025 Mar 6;12(1):e21200037. doi: 10.14440/bladder.2024.0062. eCollection 2025. Bladder (San Franc). 2025. PMID: 40747121 Free PMC article. Review.
-
Identification of m5C RNA modification-related gene signature for predicting prognosis and immune microenvironment-related characteristics of heart failure.Hereditas. 2025 May 22;162(1):83. doi: 10.1186/s41065-025-00454-z. Hereditas. 2025. PMID: 40405297 Free PMC article.
References
-
- Siegel RL, Miller KD, Fuchs HE, et al. . Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. - PubMed
-
- Rose TL, Milowsky MI. Improving systemic chemotherapy for bladder cancer. Curr Oncol Rep. 2016;18:27. - PubMed
-
- Craig AJ, von Felden J, Garcia-Lezana T, et al. . Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139–52. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials